<i>S100A8</i> (rs3806232) gene polymorphism and S100A8 serum level in psoriasis vulgaris patients: A preliminary study

Farag, Azza Gaber Antar; Shoaib, Mohamed Abd AlMoneam; Labeeb, Azza Zagloul; Sleem, Asmaa; Hussien, Hend Abdallah Abd El-Wahab; Elshaib, Mustafa Elsayed; Hanout, Hayam Mohamed Aboelnasr

doi:10.1111/jocd.14928

Cited by 3 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a promising inflammatory biomarker, serum CLP has been found useful in monitoring disease activity and treatment response in rheumatoid arthritis and ankylosing spondylitis [ 15 – 17 ]. In PsO, serum CLP was related to the severity of skin lesions [ 18 , 19 ]. With regard to PsA, the conclusion of the correlation varies.…”

Section: Discussionmentioning

confidence: 99%

Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study

Song

et al. 2022

Rheumatol Ther

View full text Add to dashboard Cite

Introduction There are few biomarkers correlated with psoriatic arthritis (PsA). We aimed to explore the clinical value of calprotectin (CLP) in PsA in disease activity and treatment targets. Methods Serum CLP was detected by enzyme-linked immunosorbent assay (ELISA) in 71 patients with PsA, 55 patients with psoriasis (PsO), and 10 healthy controls. The association of serum CLP with disease activity index at baseline and follow-up was analyzed. Cox regression and receiver operating characteristic (ROC) analysis were used to evaluate the potential of CLP for predicting the achievement of treatment targets, including low disease activity (LDA), remission, and minimal disease activity (MDA). Results Serum CLP levels (μg/ml) were significantly increased in patients with PsA/PsO compared with healthy controls ( p < 0.001). Serum CLP levels were positively associated with psoriasis area and severity index (PASI), disease activity in psoriatic arthritis (DAPSA), and its components [including tender joint count (TJC), swollen joint count (SJC), patient’s global assessment (PGA), and visual analog scale (VAS)-pain, r 0.290–0.601, all p value < 0.05]. After 1-year follow-up, the number of patients with PsA in remission and MDA increased [17 (23.9%) versus 47 (66.1%) and 21 (29.5%) versus 52 (73.2%) respectively, all p value < 0.001]. Cox regression and Kaplan–Meier survival analysis indicated that patients with lower CLP obtain LDA, MDA, and remission earlier, including remission and MDA within a year (all p -value < 0.05). ROC analysis showed the ability of serum at baseline to predict the achievement of the treatment target in 3 months [area under the curve (AUC) 0.663–0.691, all p -values < 0.05]. Conclusions Serum CLP level was correlated with disease activity in PsA. It also possessed the ability to predict the achievement of the therapeutic target. These features of CLP would make it a useful tool in clinical work. Supplementary Information The online version contains supplementary material available at 10.1007/s40744-022-00501-5.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study

Song

et al. 2022

Rheumatol Ther

View full text Add to dashboard Cite

show abstract

Etiopathogenesis of Psoriasis: Integration of Proposed Theories

Hernandez-Nicols,

Robledo-Pulido,

Alvarado-Navarro

2024

Immunological Investigations

View full text Add to dashboard Cite

Multi-Omics Research Strategies for Psoriasis and Atopic Dermatitis

Guo¹,

Luo²,

Zhu³

et al. 2023

IJMS

View full text Add to dashboard Cite

Psoriasis and atopic dermatitis (AD) are multifactorial and heterogeneous inflammatory skin diseases, while years of research have yielded no cure, and the costs associated with caring for people suffering from psoriasis and AD are a huge burden on society. Integrating several omics datasets will enable coordinate-based simultaneous analysis of hundreds of genes, RNAs, chromatins, proteins, and metabolites in particular cells, revealing networks of links between various molecular levels. In this review, we discuss the latest developments in the fields of genomes, transcriptomics, proteomics, and metabolomics and discuss how they were used to identify biomarkers and understand the main pathogenic mechanisms underlying these diseases. Finally, we outline strategies for achieving multi-omics integration and how integrative omics and systems biology can advance our knowledge of, and ability to treat, psoriasis and AD.

show abstract

S100A8 (rs3806232) gene polymorphism and S100A8 serum level in psoriasis vulgaris patients: A preliminary study

Cited by 3 publications

References 33 publications

Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study

Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study

Etiopathogenesis of Psoriasis: Integration of Proposed Theories

Multi-Omics Research Strategies for Psoriasis and Atopic Dermatitis

Contact Info

Product

Resources

About